

**Cipla Limited**  
 Regd. Office:  
 Mumbai Central  
 Mumbai 400 008

**STATEMENT OF CONSOLIDATED AUDITED RESULTS  
 FOR THE YEAR ENDED 31<sup>ST</sup> MARCH, 2013**

*(₹ in crores)*

Particulars	Year Ended	
	31.03.2013	31.03.2012
<b>1. Income from operations</b>		
a) Net sales/Income from operations (Net of excise duty)	<b>8086.82</b>	6847.70
b) Other operating income	<b>192.51</b>	173.01
<b>Total income from operations (net)</b>	<b>8279.33</b>	7020.71
<b>2. Expenses</b>		
a) Cost of materials consumed	<b>2728.92</b>	2326.35
b) Purchases of stock-in-trade	<b>514.30</b>	407.30
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	<b>(290.60)</b>	5.65
d) Employee benefits expense	<b>1036.26</b>	772.50
e) Depreciation and amortisation expense	<b>330.48</b>	312.22
f) Other expenses	<b>2092.60</b>	1850.06
<b>Total expenses</b>	<b>6411.96</b>	5674.08
<b>3. Profit (+)/Loss (-) from operations before other income and finance costs (1-2)</b>	<b>1867.37</b>	1346.63
<b>4. Other income</b>	<b>222.14</b>	139.52
<b>5. Profit (+)/Loss (-) before finance costs (3+4)</b>	<b>2089.51</b>	1486.15
<b>6. Finance costs</b>	<b>33.91</b>	38.34
<b>7. Profit (+)/Loss (-) before Exceptional Items and tax (5-6)</b>	<b>2055.60</b>	1447.81
<b>8. Exceptional Item</b>	<b>39.77</b>	-
<b>9. Profit (+)/Loss (-) before tax (7+8)</b>	<b>2095.37</b>	1447.81
<b>10. Tax expense</b>	<b>544.31</b>	306.51
<b>11. Net Profit (+)/Loss (-) after tax (9-10)</b>	<b>1551.06</b>	1141.30
<b>12. Share of Profit (+) / Loss (-) of associates</b>	<b>(6.21)</b>	2.94
<b>13. Net Profit (+) / Loss (-) for the period (11+12)</b>	<b>1544.85</b>	1144.24
<b>14. Paid-up equity share capital (Face Value ₹2 per share)</b>	<b>160.58</b>	160.58
<b>15. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year</b>	<b>8849.13</b>	7469.38
<b>16. Basic and diluted earnings per share (₹)</b>	<b>19.24</b>	14.25

Particulars	Year Ended	
	31.03.2013	31.03.2012
<b>PARTICULARS OF SHAREHOLDING</b>		
<b>1. Public shareholding</b>		
- Number of shares	<b>500983877</b>	506720722
- Percentage of shareholding	<b>62.40</b>	63.11
<b>2. Promoters and Promoter Group Shareholding</b>		
a) Pledged/Encumbered		
- Number of shares	<b>NIL</b>	NIL
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	<b>NIL</b>	NIL
- Percentage of shares (as a % of the total share capital of the company)	<b>NIL</b>	NIL
b) Non-Encumbered		
- Number of shares	<b>295485978</b>	295485978
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	<b>100.00</b>	100.00
- Percentage of shares (as a % of the total share capital of the company)	<b>36.80</b>	36.80

Notes:

- The Company is essentially in the pharmaceutical business segment.
- The Directors at their meeting held today recommended payment of dividend of ₹ 2 per equity share (face value ₹2) for the year 2012-2013 amounting to ₹ 160.58 crores.
- The consolidated accounts have been prepared in accordance with the principles set out in Accounting Standard 21 - Consolidated Financial Statements, Accounting Standard 23 - Accounting for Investments in Associates and Accounting Standard 27 – Financial Reporting in Joint Ventures in Consolidated Financial Statements notified in the Companies (Accounting Standard) Rules 2006. The financial results of associates and joint venture have been included in the consolidated results on the basis of management accounts not reviewed by the auditors.
- Exceptional Item represents profit on sale of investment in Desano Holdings Ltd by subsidiaries.
- In 2003, the Company received notice of demand from the National Pharmaceutical Pricing Authority, Government of India on account of alleged overcharging in respect of certain drugs under the Drug Price Control Order. This was contested before the jurisdictional High Courts in Mumbai, Karnataka and Allahabad wherein it was held in favour of the Company. The orders of Hon'ble High Court of Allahabad and Bombay were challenged before the Hon'ble Supreme Court of India by the Government. Although in the challenge to the decision of the Hon'ble Bombay High Court, the Hon'ble Supreme Court of India restored the matter to the Hon'ble Bombay High Court in August 2003 for interpreting the Drug Policy on the basis of directions and principles laid down by them and the same was pending, in the challenge to the Hon'ble High Court of Allahabad's order, in Feb 2013, the Hon'ble Supreme Court of India transferred the Bombay High Court petition also before itself for a final hearing on both the matters. In an earlier order, the Hon'ble Supreme Court has already restrained the government from taking any coercive action against the company. The Company has been legally advised that on the basis of these orders there is no probability of demand crystallising. Hence no provision is considered necessary in respect of notice of demand aggregating to Rs.1654.92 crores (inclusive of principal amount for the period July 1995 to April 2009 and interest upto January 2012).
- On 15th May 2013 the shareholders of Cipla Medpro South Africa Limited ("Medpro"), a company incorporated in the Republic of South Africa and listed on JSE Limited, have approved the Scheme of Arrangement ("Scheme") for the Company to acquire 100% of the ordinary share capital of Medpro at a price of ZAR 10 per share, and to settle all outstanding options to acquire Medpro shares. Based on Medpro's current shares and share options outstanding, the total consideration payable would be approximately ZAR 4518 million (approximately Rs. 2666 crores). Medpro is a distributor of Company's products in South Africa and certain neighbouring countries. Implementation of the Scheme is still subject to regulatory and other approvals and conditions.
- The Audited Standalone financial results is available on the Company's website i.e. www.cipla.com. The key standalone financial information for the year 2012-2013 are as under:
  - Total income from operations (net): ₹8202.42 crore (previous year ₹6977.50 crore)
  - Profit before tax: ₹2011.86 crore (previous year ₹1421.46 crore)
  - Profit after tax: ₹1507.11 crore (previous year ₹1123.96 crore)
- The figures of the previous year have been regrouped/recast to render them comparable with the figures of the current year.

9. The Audited Consolidated Statement of assets and liabilities is as under:

(₹ in crores)

Particulars	Year ended	
	31.03.2013	31.03.2012
<b>A. EQUITY AND LIABILITIES</b>		
<b>1. Shareholders' fund</b>		
(a) Share capital	160.58	160.58
(b) Reserves and surplus	8858.10	7478.35
<b>Shareholders' fund</b>	<b>9018.68</b>	<b>7638.93</b>
<b>2. Non-current liabilities</b>		
(a) Long-term borrowings	0.55	3.25
(b) Deferred tax liabilities (net)	280.54	233.24
(c) Other long-term liabilities	30.00	30.00
(d) Long-term provisions	50.37	31.17
<b>Non-current liabilities</b>	<b>361.46</b>	<b>297.66</b>
<b>3. Current liabilities</b>		
(a) Short-term borrowings	966.38	10.20
(b) Trade payables	828.36	691.77
(c) Other current liabilities	250.89	489.93
(d) Short-term provisions	232.00	221.29
<b>Current liabilities</b>	<b>2277.63</b>	<b>1413.19</b>
<b>Total</b>	<b>11657.77</b>	<b>9349.78</b>
<b>B. ASSETS</b>		
<b>1. Non-current assets</b>		
(a) Fixed assets	3609.97	3215.49
(b) Capital Work-in-Progress- Tangible	367.44	371.17
(c) Intangible Asset under Development	10.35	-
(d) Non-current investments	415.69	328.59
(e) Long-term loans and advances	357.80	372.35
(f) Other non-current assets	5.11	5.37
<b>Non-current assets</b>	<b>4766.36</b>	<b>4292.97</b>
<b>2. Current assets</b>		
(a) Current investments	2116.75	940.52
(b) Inventories	2387.07	1850.08
(c) Trade receivables	1668.84	1553.58
(d) Cash and cash equivalents	143.01	90.46
(e) Short-term loans and advances	573.46	568.19
(f) Other current assets	2.28	53.98
<b>Current assets</b>	<b>6891.41</b>	<b>5056.81</b>
<b>Total</b>	<b>11657.77</b>	<b>9349.78</b>

10. The above results after being reviewed by the Audit Committee were approved at the meeting of the Board of Directors held on 29<sup>th</sup> May, 2013.

By order of the Board  
For **CIPLA LIMITED**

Mumbai  
29<sup>th</sup> May, 2013

**M. K. Hamied**  
Managing Director